PT - JOURNAL ARTICLE AU - YOUNG KIM AU - JOHN W. STREHL AU - MARCUS GORSCHLÜTER AU - CARSTEN ZISKE AU - INGO G.H. SCHMIDT-WOLF TI - Prevention of Lethal Tumor Growth and Generation of Long-lasting Immunity <em>In Vivo</em> Using CD137L and Interleukin-12 Gene Transfer DP - 2008 May 01 TA - In Vivo PG - 337--343 VI - 22 IP - 3 4099 - http://iv.iiarjournals.org/content/22/3/337.short 4100 - http://iv.iiarjournals.org/content/22/3/337.full SO - In Vivo2008 May 01; 22 AB - In a wide range of solid tumors, overexpression of CD137L has been shown to induce tumor immunity partly due to the stimulation of CD8+ CTL, which was even increased when immunotherapy with interleukin-12 (IL12) was additionally employed. However, little in known regarding hematologic neoplasias in this respect. Of the 8 animals receiving IL12-secreting tumor cells, 2 died. Animals treated with CD137L-expressing tumor cells and the combination group, all animals survived. Interestingly, re-challenge with wild-type tumor cells was rejected by all animals in the CD137L group and all remaining animals in the IL12 group, while these in the control group died. IL12- and CD137L-transfected plasmocytoma cells prevented tumor growth and induced long-lasting immunity. Our results warrant follow-up for future clinical use in patients with myeloma.